During the past decade, Avera Hematology and Transplant conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Avera Hematology and Transplant" are "Diffuse Large B-cell Lymphoma" (1 trials), "Follicle Center Lymphoma" (1 trials), "MPN-associated Myelofibrosis" (1 trials) and "Primary Myelofibrosis" (1 trials). Many other conditions were trialed in "Avera Hematology and Transplant" in a lesser frequency.

Most popular intervention types in "Avera Hematology and Transplant" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "In-111 Zevalin" (1 trials), "Placebo" (1 trials), "Pomalidomide" (1 trials), "Pomalidomide 0.5 mg" (1 trials) and "Rituximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Avera Hematology and Transplant" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Avera Hematology and Transplant". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Avera Hematology and Transplant, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Avera Hematology and Transplant, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".